Search results
ASCO24: Enhertu aims to replace Herceptin in first-line metastatic breast cancer
Pharmaceutical Technology via Yahoo Finance· 11 hours agoInterim safety and efficacy results of the Phase Ib/II Destiny-BREAST07 trial with Enhertu...
AstraZeneca stock upgraded by Goldman, 27% upside seen By Investing.com
Investing.com· 4 days agoOn Thursday, Goldman Sachs (NYSE:GS) initiated coverage on AstraZeneca (NASDAQ:AZN:LN) (NASDAQ: AZN)...
AstraZeneca started at buy at Goldman, which rates GSK a neutral
Morningstar· 4 days agoGoldman Sachs started coverage of AstraZeneca at buy as it rated rival pharmaceutical company GSK a neutral. Analysts led by Rajan Sharma said AstraZeneca
JPMorgan bullish on AstraZeneca stock, highlights AZD0780's sales By Investing.com
Investing.com· 6 days agoOn Tuesday, JPMorgan (NYSE:JPM) maintained its positive stance on AstraZeneca (NASDAQ:AZN:LN)...
AstraZeneca CEO Has No Plans to Retire as He Seeks to Nearly Double Sales by 2030
The Wall Street Journal· 3 days agolongest-serving chief executive, Pascal Soriot, has no plans to step down for now as the company...
AstraZeneca-Daiichi's Enhertu follow-up Dato-DXd unable to prove overall survival benefit in phase 3
FierceBiotech· 6 days agoDaiichi Sankyo and antibody-drug conjugate (ADC) partner AstraZeneca have already filed their...
Tempus launches new HER2 and FOLR1 testing solutions
Medical Device Network via Yahoo Finance· 54 minutes ago“These are the kind of critical tools that we are arming physicians with as new, targeted therapies are made available for patients.” In a separate...
Earnings call: Cellectis reports an additional investment of $140 million from AstraZeneca By...
Investing.com· 4 days agoIn their first quarter 2024 earnings call, Cellectis, a biopharmaceutical company, presented a...
AstraZeneca (AZN) Falls on Failure to Meet NSCLC Study OS Goal
Zacks· 5 days agoAstraZeneca's (AZN) shares decline as it fails to achieve statistically significant overall survival data in a late-stage NSCLC study on Dato-DXd compared with docetaxel.
AstraZeneca (NASDAQ:AZN) Now Covered by Analysts at The Goldman Sachs Group
ETF DAILY NEWS· 3 days agoThe Goldman Sachs Group assumed coverage on shares of AstraZeneca (NASDAQ:AZN – Free Report) in a research report report published on Thursday morning, Marketbeat Ratings ...
